Literature DB >> 14677076

Anhedonia, self-experience in schizophrenia, and implications for treatment.

G Juckel1, L Sass, A Heinz.   

Abstract

Anhedonia - the inability to experience pleasure - is a symptom of several psychiatric disorders such as depression, drug and alcohol dependence, but also schizophrenia. The concept of anhedonia played a major role in psychiatric and psychoanalytic explanations of psychotic behavior. The relationship between notions of anhedonia and of mental evolution and regression (in the work of Myerson and Bleuler) is discussed. The non-evolutionist views of Rado and Meehl are described. Then the concept of anhedonia is discussed in relationship to the phenomenological approach of Sass and Parnas, who view anhedonia as one manifestation of a self-disturbance or self-disorder that is fundamental in schizophrenia. Concerning treatment of anhedonia, it was often hypothesized that anhedonia is associated with a dysfunction of the mesolimbic dopaminergic reward system. However, studies in humans and non-human animal models indicate that dysfunction of central dopaminergic neurotransmission interferes with the process of motivation rather than with the ability to experience pleasure; the latter may be more mediated by the opioidergic and serotonergic neurotransmission. Understanding the neurobiological correlates of motivation and pleasure may provide new options to treat anhedonia in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677076     DOI: 10.1055/s-2003-45127

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

Review 1.  The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

Authors:  John H Krystal; D Cyril D'Souza; Jürgen Gallinat; Naomi Driesen; Anissa Abi-Dargham; Ismene Petrakis; Andreas Heinz; Godfrey Pearlson
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 2.  CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease.

Authors:  Shambhu Bhat; David T Dao; Chantelle E Terrillion; Michal Arad; Robert J Smith; Nikolai M Soldatov; Todd D Gould
Journal:  Prog Neurobiol       Date:  2012-06-15       Impact factor: 11.685

3.  Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.

Authors:  Byron K Y Bitanihirwe; Daria Peleg-Raibstein; Forouhar Mouttet; Joram Feldon; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

4.  Developmental exposure of rats to chlorpyrifos leads to behavioral alterations in adulthood, involving serotonergic mechanisms and resembling animal models of depression.

Authors:  Justin E Aldridge; Edward D Levin; Frederic J Seidler; Theodore A Slotkin
Journal:  Environ Health Perspect       Date:  2005-05       Impact factor: 9.031

5.  A comparative study of anhedonia components between major depression and schizophrenia in Chinese populations.

Authors:  Yinghui Li; Xiaodong Mou; Wenhao Jiang; Zhong Yang; Xinhua Shen; Zhuma Jin; Zhiping Dai; Yuju Liu; Shengqin Mao; Jian Zhang; Yonggui Yuan
Journal:  Ann Gen Psychiatry       Date:  2015-09-03       Impact factor: 3.455

Review 6.  Inhibition of the reward system by antipsychotic treatment.

Authors:  Georg Juckel
Journal:  Dialogues Clin Neurosci       Date:  2016-03       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.